Despite the advent of BCR-ABL targeting tyrosine kinase inhibitors (TKIs), a small percentage of patients progress from a prior chronic or accelerated phase (CP/AP) to blast phase CML (CML-BP). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.